Green Cross Corporation
Records under this name other than the patents Green Cross Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 40 patents it holds.
Back to Green Cross Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,524,054 | Method of treating anemia using long-acting EPO formulation Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,889,574 | Method for Producing Diphenylmethane Derivative Held by another company In force · Medium confidence | In force | Medium confidence | |
| US 11,401,343 | Anti-Msln Antibody and Pharmaceutical Composition for Cancer Treatment Comprising Same Formerly held In force · High confidence | In force | High confidence | |
| US 8,840,895 | Human Antibodies Specifically Binding to the Hepatitis B Virus Surface Antigen Lapsed on the fee record Ended Sep 23, 2026 · High confidence | Lapsed on the fee record | Ended Sep 23, 2026 | High confidence |
| US 11,447,559 | Anti-Bcma Antibody Having High Affinity for Bcma and Pharmaceutical Composition for Treatment of Cancer, Comprising Same Formerly held Lapsed on the fee record Ended Sep 20, 2026 · High confidence | Lapsed on the fee record | Ended Sep 20, 2026 | High confidence |
| US 8,748,175 | Antibodies specifically binding to the epidermal growth factor receptor Lapsed on the fee record Ended Jun 10, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 10, 2026 | USPTO record |
| US 11,332,528 | Anti-CEACAM1 antibody and use thereof Lapsed on the fee record Ended May 17, 2026 · USPTO record | Lapsed on the fee record | Ended May 17, 2026 | USPTO record |
| US 11,198,733 | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor Lapsed on the fee record Ended Dec 14, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 14, 2025 | USPTO record |
| US 9,683,029 | Antibody composition for prevention or treatment of mutant hepatitis B virus infection Lapsed on the fee record Ended Jun 20, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | USPTO record |
| US 10,918,717 | Pharmaceutical formulation comprising anti-EGFR antibody Lapsed on the fee record Ended Feb 16, 2025 · USPTO record | Lapsed on the fee record | Ended Feb 16, 2025 | USPTO record |